PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis

20260 citationsJournal Articlehybrid Open Access

Authors

Yushang Yang · Sichuan University

Xiaolong Yan · Tang Du Hospital

H J Jiang · Tianjin Medical University Cancer Institute and Hospital

Mingqiang Kang · Fujian Medical University

Xinyu Mei · University of Science and Technology of China

Lijie Tan · Fudan University

Junfeng Liu ·

Abstract

Tislelizumab with chemotherapy/chemoradiotherapy as neoadjuvant treatment for resectable ESCC yielded promising pCR rates and favorable survival outcomes with a tolerable safety profile in both PET-/CT-guided responders and PET nonresponders.

Topics & Keywords

Esophageal Cancer Research and Treatment Cancer Immunotherapy and Biomarkers Colorectal and Anal Carcinomas

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-25-2367

Field-Weighted Citation Impact: 0.00